COVID-19 Vaccination FAQs

Frequently asked Information about the COVID-19 Vaccine

It has been announced that the COVID-19 booster programme will be starting shortly. The JCVI is advising that booster vaccines be offered to those more at risk from serious disease, and who were vaccinated during Phase 1 of the vaccine programme (priority groups 1 to 9). This includes:

Those living in residential care homes for older adults
All adults aged 50 years or over
Frontline health and social care workers
All those aged 16 to 49 years with underlying health conditions that put them at higher risk of severe COVID-19), and eligible adult carers
Adults living with people who are immunosuppressed

 

The JVCI advises that the booster vaccination should be offered no earlier than 6 months after a person’s 2nd dose. The JVCI advises a preference for the Pfizer vaccine for the booster programme, regardless of which vaccine brand someone received for their primary doses. Alternatively, a half dose of the Moderna vaccine may be offered.

It will take the NHS time to get through people who will be offered a booster. Locally, we will work through the priority list and offer to those greatest at risk, moving down the age groups as we did before.

We would ask that you please don’t contact your GP practice about this. Please be assured that you will be invited when the NHS is able to offer you an appointment.

You can find more information about this on the gov.uk website.

Healthy children aged 12- 15 years

It has now been announced that healthy children aged 12 – 15 will receive one dose of the COVID-19 vaccination. This vaccination programme will be delivered in schools.

Vaccination will be carried out by school-aged immunisation service (SAIS) providers, a group of provider organisations such as NHS community trusts who are contracted in local systems to provide routine immunisation services such as flu. The intention is for most school visits to be completed before October half term break.

Parents or guardians of children aged 12-15 will begin to receive letters from their local school-aged immunisation service provider with details of when the vaccination will be offered. For most children, this will be through a session at their school.

They will also be asked to provide consent for their child to receive the vaccination, either through an online or a paper form.

Parents or guardians do not need to contact their local GP or other NHS services, nor make an appointment through the National Booking Service. A process will be in place to exclude children that have already received a first dose under previous JCVI advice.

At this time, the advice is that 12-15 year olds should be offered a first dose only of the Pfizer vaccine, the only vaccine currently authorised for this age group.

Children aged 12 – 15 at greater risk

A small group of children have been eligible for COVID vaccination as they are at higher risk from COVID infection due to having one of the conditions listed below. For these children, the advice remains that they will be offered two vaccines.  These vaccines are being delivered by GP practices  who were asked to prioritise these children and offer a vaccine before the new school year.

Chronic respiratory diseaseIncluding those with poorly controlled asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, cystic fibrosis, ciliary dyskinesias and bronchopulmonary dysplasia
Chronic heart conditionsHaemodynamically significant congenital and acquired heart disease, or less severe heart disease with other co-morbidity
Chronic conditions of the kidney, liver or digestive systemIncluding those associated with congenital malformations of the organs, metabolic disorders and neoplasms, and conditions such severe gastro-oesophageal reflux that may predispose to respiratory infection
Chronic neurological diseaseThis includes those with

• neuro-disability and/or neuromuscular disease including cerebral palsy, autism, epilepsy and muscular dystrophy.

• hereditary and degenerative disease of the nervous system or muscles. or other conditions associated with hypoventilation.

• severe or profound and multiple learning disabilities (PMLD), Down’s syndrome, those on the learning disability register,

• neoplasm of the brain.

Endocrine disordersIncluding diabetes mellitus, Addison’s and hypopituitary syndrome
Immunosuppression – 3 doses for those meeting the criteria of severe immunosuppression at the time of vaccinationImmunosuppression due to disease or treatment, including:

• those undergoing chemotherapy or radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients

• genetic disorders affecting the immune system (e.g. deficiencies of IRAK-4 or NEMO, complement disorder, SCID)

• those with haematological malignancy, including leukaemia and lymphoma

• those receiving immunosuppressive or immunomodulating biological therapy

• those treated with or likely to be treated with high or moderate dose corticosteroids

• those receiving any dose of non-biological oral immune modulating drugs e.g. methotrexate, azathioprine, 6-mercaptopurine or mycophenolate

• those with auto-immune diseases who may require long term immunosuppressive treatments

Asplenia or dysfunction of the spleenIncluding hereditary spherocytosis, homozygous sickle cell disease and thalassemia major
Serious genetic abnormalities that affect a number of systemsIncluding mitochondrial disease and chromosomal abnormalities
Household contacts of immunosuppressed individualsThe child shares living accommodation on most days (and therefore for whom continuing close contact is unavoidable) with individuals of any age who are immunosuppressed

If you think your child, or a child you care for aged 12-15 years old, is eligible for COVID vaccination please contact their GP Practice to arrange a vaccination appointment or to discuss vaccination.

For more information about COVID vaccination for children and young people please see the information available here:

COVID-19 vaccination: a guide for eligible children and young people – GOV.UK (www.gov.uk)

For healthy 12-15 year olds, vaccination will be carried out by school-aged immunisation service in schools. These are a group of provider organisations such as NHS community trusts who are contracted to provide routine immunisation services such as flu.

As with all vaccinations, a consent form and information leaflet provided by the school-aged immunisation service team will be used to seek consent from parents or those with parental responsibility. Parents will also be provided with a contact number for the school-aged immunisation service team in case of any queries. Consent forms should be returned by the deadline agreed with the team.

Some children may be sufficiently mature to provide their own consent if their parents have not returned a consent form and they express a wish to have a vaccine on the day of the session. Trained professionals in the SAIS team, with expertise in vaccinating children and assessing consent, will speak to the child to assess intelligence, competence and understanding to fully appreciate what’s involved in their treatment, to determine appropriateness of administering the vaccine. This will include making every effort to contact the parent to seek their verbal consent and an assessment of the individual child’s capacity to self-consent, where appropriate.

The COVID-19 vaccination consent form for children and young people can be found at www.gov.uk/government/publications/covid-19-vaccination-resources-for-children-and-young-people.

Where can I get my vaccine from?

You can ring 01942 807780 to book a vaccine appointment (1st or 2nd dose) at any of the local clinics.  Or if you still need your first dose and find it easier to just head down without an appointment, check out our list of walk-in clinics.  These walk-in clinics are for first doses only at the moment.

Alternatively, you can book through the national booking service at www.nhs.uk/covid-vaccination or by phoning 119. You will be given the option of attending a local participating pharmacy or vaccination centre.

It’s really important that  you have the vaccine, as you will be protecting yourself and friends and family around you.

Can I contact my GP to arrange a vaccination appointment ? 

We would encourage you, where possible ring 01942 807780 to book for your vaccine.

I fall in to one of the first Cohorts – how can I get my vaccine?

All cohorts are now eligible, so that is everyone aged 16 and above.  It’s important you are vaccinated as soon as possible.  Please ring 01942 807780 to book your appointment, or contact the national booking service at www.nhs.uk/covid-vaccination or by phoning 119.

What about getting my second dose of the vaccine?

If you have already had one dose of the vaccine, you will be able to get your second dose using the same service as with your first. NHS guidelines are for you to have your second dose on or after 8 weeks.  You can ring 01942 807780 if you are at the time for your second vaccine and you haven’t got an appointment.

Please note that healthy children and young people aged 12 – 17 will only be offered one dose of the vaccine, as per current JVCI guidance.

 Where can I get more information about the vaccine?

You can find more information about the COVID-19 vaccination programme NHS.UK website.

The clinical risk groups for people aged 16 years of age or over who should receive COVID-19 immunisation are  below.

Chronic respiratory disease
Individuals with a severe lung condition, including those with asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia (BPD).

Chronic heart disease and vascular disease
Congenital heart disease, hypertension with cardiac complications, chronic heart failure, individuals requiring regular medication and/or follow-up for ischaemic heart disease. This includes individuals with atrial fibrillation, peripheral vascular disease or a history of venous thromboembolism.

Chronic kidney disease
Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic syndrome, kidney transplantation.

Chronic liver disease
Cirrhosis, biliary atresia, chronic hepatitis.

Chronic neurological disease
Stroke, transient ischaemic attack (TIA). Conditions in which respiratory function may be compromised due to neurological disease (e.g. polio syndrome sufferers). This includes individuals with cerebral palsy, severe or profound learning disabilities, Down’s Syndrome, multiple sclerosis, epilepsy, dementia, Parkinson’s disease, motor neurone disease and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability.

Diabetes mellitus
Any diabetes, including diet-controlled diabetes.

Immunosuppression
Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).
Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.
Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.
Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma and those with systemic lupus erythematosus and rheumatoid arthritis, and psoriasis who may require long term immunosuppressive treatments.
Most of the more severely immunosuppressed individuals in this group should already be flagged as CEV. Individuals who are not yet on the CEV list but who are about to receive highly immunosuppressive interventions or those whose level of immunosuppression is about to increase may be therefore be offered vaccine alongside the CEV group, if therapy can be safely delayed or there is sufficient time (ideally two weeks) before therapy commences.
Some immunosuppressed patients may have a suboptimal immunological response to the vaccine (see Immunosuppression and HIV).

Asplenia or dysfunction of the spleen
This also includes conditions that may lead to splenic dysfunction, such as homozygous sickle cell disease, thalassemia major and coeliac syndrome.

Morbid obesity
Adults with a Body Mass Index ≥40 kg/m².

Severe mental illness
Individuals with schizophrenia or bipolar disorder, or any mental illness that causes severe functional impairment.

Adult carers
Those who are eligible for a carer’s allowance, or those who are the sole or primary carer of an elderly or disabled person who is at increased risk of COVID-19 mortality and therefore clinically vulnerable.

Younger adults in long-stay nursing and residential care settings
Many younger adults in residential care settings will be eligible for vaccination because they fall into one of the clinical risk groups above (for example learning disabilities). Given the likely high risk of exposure in these settings, where a high proportion of the population would be considered eligible, vaccination of the whole resident population is recommended.
Younger residents in care homes for the elderly will be at high risk of exposure, and although they may be at lower risk of mortality than older residents should not be excluded from vaccination programmes.

 

This information was taken from the COVID-19 Greenbook chapter 14a which can be accessed here.

This also states that the examples above are not exhaustive, and, within these groups, the prescriber should apply clinical judgment to take into account the risk of COVID-19 exacerbating any underlying disease that a patient may have, as well as the risk of serious illness from COVID-19 itself.  If you think you fall into one of these groups, but don’t see your specific illness or condition mentioned, our advice would be to talk to your GP who will apply their own clinical judgement.

The Pfizer/BioNTech, Oxford/AstraZeneca  and Moderna COVID-19 vaccines are available. All vaccines have been shown to be safe and offer high levels of protection, and have been given regulatory approval by the MHRA.

You cannot usually choose which vaccine you have. When you book, you’ll only be offered appointments for vaccines that are suitable for you.

Most people can have any of the COVID-19 vaccines, but some people are only offered certain vaccines.

For example:

If you’re pregnant or under 40 you’ll usually be offered appointments for the Pfizer/BioNTech or Moderna vaccines
If you’re under 18, you’ll only be offered the Pfizer/BioNTech vaccine

You should have the same vaccine for both doses, unless you had serious side effects (such as a serious allergic reaction) after your 1st dose.

Yes. The NHS will not offer any Covid-19 vaccinations to the public until independent experts have signed off that it is safe to do so.

The MHRA, the official UK regulator, have said these vaccines are safe and highly effective, and we have full confidence in their expert judgement and processes.

As with any medicine, vaccines are highly regulated products.

There are checks at every stage in the development and manufacturing process, and continued monitoring once it has been authorised and is being used in the wider population.

The MHRA recommend that those with severe allergies to the ingredients of the vaccines should not receive them.

Getting your COVID-19 vaccination as soon as you can, should protect you and may help to protect your family and those you care for.

The COVID-19 vaccine should help reduce the rates of serious illness and save lives and will therefore reduce pressure on the NHS and social care services.

The Joint Committee for Vaccination and Immunisation (JCVI) published its final advice which can be found here.

The NHS is currently offering the coronavirus (COVID-19) vaccine to people most at risk from coronavirus.

People in the groups on the NHS website  can get the vaccine now. The vaccine will be offered more widely as soon as possible.

The MHRA have said these vaccines are highly effective, but to get full protection people need to come back for the second dose – this is really important.

To ensure as many people are vaccinated as quickly as possible, the Department for Health and Social Care now advise that the second dose of both the OxfordAstraZeneca and the Pfizer/BioNtech vaccine should be scheduled up to 12 weeks apart.

Full protection kicks in around a week or two after that second dose, which is why it’s also important that when you receive your second dose for maximum immunity.

The phase three study of the Pfizer BioNTech COVID-19 vaccine demonstrated a vaccine efficacy of 95%, with consistent efficacy across age, gender and ethnicity. Overall, among the participants who received the COVID-19 vaccine 82.1% were White, 9.6% were Black or African American, 26.1% were Hispanic/Latino, 4.3% were Asian and 0.7% were Native American/Alaskan.

People currently unwell and experiencing COVID-19 symptoms should not receive the COVID-19 vaccine until they have recovered.

Yes, they should get vaccinated if they are in a priority group identified by JCVI. The MHRA have looked at this and decided that getting vaccinated is just as important for those who have already had Covid-19 as it is for those who haven’t.

. There is no evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody, so people who have had COVID-19 disease (whether confirmed or suspected) can still receive the COVID-19 vaccine when it is their time to do so.

A detailed review of the vaccines and their ingredients have been provided by the MHRA and can be found at the following links:

For the Pfizer/BioNTech vaccine information is available here: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19

For the Oxford/AstraZeneca vaccine information is available here: https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca

For the Moderna vaccine information is available here: Regulatory approval of Spikevax (formerly COVID-19 Vaccine Moderna) – GOV.UK (www.gov.uk)

The British Islamic Medical Association have produced a helpful guide for the Muslim community which can be found at https://britishima.org/pfizer-biontech-covid19-vaccine/

There is no material of foetal or animal origin in either vaccine. All ingredients are published in healthcare information on the MHRA’s website.

For the Pfizer/BioNTech vaccine information is available here: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19

For the Oxford/AstraZeneca vaccine information is available here: https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca

For the Moderna vaccine information is available here: Regulatory approval of Spikevax (formerly COVID-19 Vaccine Moderna) – GOV.UK (www.gov.uk)

These are important details which the MHRA always consider when assessing candidate vaccines for use.

For these vaccines, like lots of others, they have identified that some people might feel slightly unwell, but they report that no significant side effects have been observed in the tens of thousands of people involved in trials.

All patients will be provided with information on the vaccine they have received, how to look out for any side effects, and what to do if they do occur, including reporting them to the MHRA.

More information on possible side effects can be found at https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/

These vaccines are safe and effective for the vast majority of people – they have been tested on tens of thousands of people and assessed by experts.

Any person with a history of immediate-onset anaphylaxis to the ingredients contained in the vaccines should not receive them. A second dose of the Pfizer/BioNTech vaccine should not be given to those who have experienced anaphylaxis to the first dose of Pfizer/BioNTech vaccination.

Everybody will also be screened for potential allergic reactions before getting vaccinated. All vaccinators will have the training they need to deal with any rare cases of adverse reactions, and all venues will be equipped to care for people who need it – just like with any other vaccine.

Like all medicines, vaccines can cause side effects. Most of these are mild and short-term, and not everyone gets them. Even if you do have symptoms after the first dose, you still need to have the second dose. You may not be protected until at least seven days after your second dose of the vaccine.

Very common side effects include:

  • Having a painful, heavy feeling and tenderness in the arm where you had your injection. This tends to be worst around 1-2 days after the vaccine
  • Feeling tired
  • Headache
  • General aches, or mild flu like symptoms

As with all vaccines, appropriate treatment and care will be available in case of a rare anaphylactic event following administration.

The flu vaccine does not protect you from COVID-19. As you are eligible for both vaccines you should have them both, but normally separated by at least a week.

No, the COVID-19 vaccine will not protect you against the flu. If you have been offered a flu vaccine, please try to have this as soon as possible to help protect you, your family  and patients.

It is not essential to leave time between the flu and Covid vaccine but it is recommended that there should be a gap of a week.

We would always encourage anyone who is eligible but not yet taken up their flu jab to do so as soon as possible.

This will be always be reviewed with the most up to date information available , so we will continue to vaccinate people as normal. Scientists are looking now in detail at the characteristics of the virus in relation to the vaccines. Viruses, such as the winter flu virus, often branch into different strains but these small variations rarely render vaccines ineffective.

The vaccines that the NHS uses and in what circumstances will be decided by the MHRA. Both vaccines are classed as being very effective. The Oxford/AstraZeneca is easier to store and transport, meaning we can deliver them in more places but the vaccine you receive will be the most appropriate for your circumstances.

Any vaccines that the NHS will provide will have been approved because they pass the MHRA’s tests on safety and efficacy, so people should be assured that whatever vaccine they get, it is worth their while.

No. Vaccinations will only be available through the NHS for the moment. Anyone who claims to be able to provide you with a vaccine for a fee is likely to be committing a crime and should be reported to the Police online or by calling 112.

Both vaccines have been authorised on the basis of two doses because the evidence from the clinical trials shows that this gives the maximum level of protection.

To ensure as many people are vaccinated as quickly as possible, the Department for Health and Social Care now advise that the second dose of both the Oxford/AstraZeneca and the Pfizer/BioNtech vaccine should be scheduled up to 12 weeks apart.

The evidence doesn’t show any risk to not having the second dose other than not being as protected as you otherwise would be. We would urge everyone to show up for both of their appointments for their own protection as well as to ensure we don’t waste vaccines or the time of NHS staff.

People with history of a severe allergy to the ingredients of the vaccines should not be vaccinated.

The MHRA have updated their guidance to say that pregnant women and those who are breastfeeding can have the vaccine but should discuss it with a clinician to ensure that the benefits outweigh any potential risks.

Although the vaccine was not tested on those with very serious immunological conditions, the vaccine has been proven to be very effective and it is unlikely that the vaccine will have no effect at all on these individuals.

There may be a very small number of people with very complex or severe immunological problems who can’t make any response at all – but the vaccine should not do any harm to these individuals. Individuals meeting these criteria may want to discuss the vaccine further with their specialist doctor.

We are aware that some people are receiving suspicious calls and text messages offering the COVID-19 vaccination.

To protect yourself and your family members from fraud and criminals, remember the following points.

  • The vaccine is only available on the NHS for free to people in priority groups, and the NHS will contact you when it is your turn. Anyone offering a paid-for vaccine is committing a crime.
  • The NHS will never ask you to press a button on your keypad or send a text to confirm you want the vaccine, and never ask for payment or for your bank details.
  • If you need to be vaccinated at home you will always be contacted prior by your GP practice or health professional. They will not just turn up on your door step. Anyone offering this now is committing a crime.

If you receive a call you believe to be fraudulent, hang up. If you believe you have been the victim of fraud or identity theft you should report this directly to Action Fraud on 0300 123 2040. Where the victim is vulnerable, and particularly if you are worried that someone has or might come to your house, report it to the Police online or by calling 101.

Skip to content